Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Erkelenz – page 84

1 570 clinical trials in Erkelenz, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Erkelenz at a glance
1 570
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 570 trials in Erkelenz

Open in trial search

Title: Long-term safety and effectiveness study of ulviprubart in patients with inclusion body myositis who completed previous treatment

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ulviprubart
  • Sponsor:Abcuro Inc.

VEXAS syndrome

Not recruiting

Study of pacritinib effectiveness and safety compared to placebo in patients with VEXAS syndrome

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pacritinib
  • Sponsor:Sobi Inc.

Multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Frexalimab and Teriflunomide for Adults with Relapsing Multiple Sclerosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on Itepekimab for Adults with Chronic Rhinosinusitis and Nasal Polyps

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study to Test if Nerandomilast (BI 1015550) Helps Patients with Interstitial Lung Disease Related to Rheumatic Diseases

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

Cholangiocarcinoma

Not recruiting

Study of Ivosidenib, Durvalumab, and Gemcitabine/Cisplatin for Patients with Advanced Cholangiocarcinoma with IDH1 Mutation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Asthma

Not recruiting

Study on the Effectiveness and Safety of Benralizumab with Budesonide and Formoterol in Patients with Eosinophilic Asthma Uncontrolled by Standard Treatment

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:AstraZeneca AB

Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Stemline Therapeutics Inc.

Crohn's disease

Not recruiting

Study on the Safety and Effectiveness of Adalimumab as Initial Treatment for Newly Diagnosed Crohn's Disease Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Universiteit Maastricht

HIV infection

Not recruiting

Study on the Effectiveness of Cabotegravir and Rilpivirine for People with HIV-1 Who Have Not Responded Well to Oral Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cabotegravir
  • Sponsor:Viiv Healthcare UK Limited

Prostate cancer

Not recruiting

Study on the Use of 18F-PSMA-1007, Piflufolastat (18F), and Gozetotide for Detecting Pelvic Lymph Node Invasion in Newly Diagnosed Prostate Cancer Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Gozetotide
  • Sponsor:Canisius Wilhelmina Ziekenhuis

Study of Eciskafusp Alfa and BCG for Patients with High-Risk Bladder Cancer Not Responding to BCG Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:RO7284755
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Erkelenz

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical trials focusing on triple-negative breast cancer evaluating the effectiveness of combining immunotherapy with traditional chemotherapy treatments. Studies aim to improve patient outcomes through personalized therapeutic approaches.

  • Triple-Negative Breast Cancer Treatment
  • Immunotherapy Integration
  • Event-Free Survival Assessment

Research explores novel combination therapies to enhance treatment efficacy.

02 Hormone Receptor Research

Studies examining personalized treatment strategies for HR+/HER2- breast cancer patients, comparing endocrine therapy combinations with standard chemotherapy approaches. Focus on long-term survival outcomes.

  • Endocrine Therapy Enhancement
  • Disease-Free Survival Analysis
  • Personalized Treatment Protocols

Investigation of targeted therapies to improve treatment effectiveness.

03 Advanced Treatment Studies

Research evaluating novel therapeutic approaches for HER2-negative breast cancer patients, particularly those at high risk of relapse after standard treatments. Focus on comparing innovative targeted therapies with conventional approaches.

  • High-Risk Patient Treatment
  • Relapse Prevention Strategies
  • Comparative Treatment Efficacy

Development of targeted solutions for challenging breast cancer cases.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.